Steven Bellon, Ph.D..

Chief Science OfficeratFoghorn Therapeutics· In proxies 2022–2025

Pay in FY2025+33% from the year before · Foghorn Therapeutics stock +14.4% the same year

Steven Bellon, Ph.D.. was paid $1.2M in FY2025 (Dec), up 33%. Foghorn Therapeutics stock rose 14.4% that year.

Pay$100 in the stock at the end of FY21 → $24

Pay is from the Summary Compensation Table of each Foghorn Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

FHTX
Foghorn TherapeuticsPublic company · 4 yr
- Chief Science Officer2022 – Present · 4 yrStock in role -90%

Roles come from the proxy statements of each company.

Activity

Pay
Foghorn Therapeutics Chief Science Officer pay rose 33% to $1.2M. The stock rose 14% in FY2025 (Dec).
DEF 14AApr 30, 2026
Pay
Foghorn Therapeutics Chief Science Officer pay fell 24% to $902.2K. The stock fell 27% in FY2024 (Dec).
DEF 14AApr 30, 2026
Pay
Foghorn Therapeutics Chief Science Officer pay fell 45% to $1.2M. The stock rose 1% in FY2023 (Dec).
DEF 14AMay 3, 2024

For the press:Download CSV Download PNG How to use our data

Two people shown as one, or a wrong number?